Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial01 first-line HER2-expressing pMMR endometrial cancer
jRCT2011250015Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised trial of trastuzumab deruxtecan in endometrial cancer (EC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jul 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2011250015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250015.